Gilead Sciences Inc (GILD – Q3FY20) – Sale of Veklury and HIV products positively affecting the growth.

HIV product sales increased by 8% to $4.5bn for Q3FY20 due to core HIV business driven by higher volume as channel inventory continues to normalize in the United States following the second quarter consumption of the stockpiling from Q1FY20, as well as stronger patient demand, including the continued patient uptake of Biktarvy and growth of Descovy for PrEP.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q3FY20 Results – Overview
– Q3FY20 – Product Revenues
– Key Developments
– FY20 – Guidance
– Conclusion
– GAAP to Non-GAAP reconciliation

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per Share Items and Key Ratios
– Key Balance Sheet and Cash Flow ratios
– P/E Band

Product Performance and Key Developments

– Ownership
– Competition
– Key Developments

Valuation and Consensus Performance

– Relative Valuation
– Analyst Recommendations

Market Price Performance

CrispIdea Coverage

No of Pages : 63